The debate between CAR T-cell therapy and bispecific antibodies is not a rivalry but a question of sequencing, ...

FDA updates talazoparib and enzalutamide labeling, confirming survival benefits for HRR-mutated mCRPC, while excluding ...

China's biotech sector is on a tear. The Hang Seng Biotech Index has climbed over 60% since Januaryhandily beating China tech ...